Table 5.

Recommendations for prostate cancer treatment during SARS-CoV-2 pandemic.

Risk group according to NCCN guidelines	Recommendations
Low risk	Treatment with active surveillance is recommended. Telemedicine consultations are recommended for follow-up and triage for those already in AS programs for repeat biopsy by DRE, PSA, genomics (eg, Oncotype MDx), MRI PIRADS score, and clinical T stage.
Intermediate risk	Patients with ISUP 2 PCa are recommended to have active monitoring. In men with ISUP 3 PCa, ADT may be considered.
High risk	Radical prostatectomy or curative radiation therapy can be performed if capacity is available. In case of deferred treatment, patients can be given ADT.

ADT = androgen deprivation therapy; AS = active surveillance; DRE = digital rectal examination; ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; NCCN = National Comprehensive Cancer Network; PCa = prostate cancer; PIRADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.